ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Purchases $3,964,656.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. bought 437,600 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, March 25th. The shares were acquired at an average cost of $9.06 per share, for a total transaction of $3,964,656.00. Following the acquisition, the director now owns 8,994,374 shares in the company, valued at approximately $81,489,028.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, March 27th, Ra Capital Management, L.P. bought 505,954 shares of ARS Pharmaceuticals stock. The shares were acquired at an average cost of $9.79 per share, for a total transaction of $4,953,289.66.

ARS Pharmaceuticals Stock Performance

Shares of ARS Pharmaceuticals stock opened at $9.96 on Thursday. The stock has a market capitalization of $961.14 million, a PE ratio of -17.47 and a beta of 0.78. ARS Pharmaceuticals, Inc. has a 52-week low of $2.55 and a 52-week high of $10.20. The company has a 50-day simple moving average of $7.75 and a two-hundred day simple moving average of $5.80.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. SVB Leerink raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $6.00 to $18.00 in a report on Tuesday, March 5th. Leerink Partnrs raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th. William Blair raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 20th. Finally, Wedbush reissued an “outperform” rating and set a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in ARS Pharmaceuticals in the fourth quarter worth about $632,000. Barclays PLC grew its stake in shares of ARS Pharmaceuticals by 127.1% in the fourth quarter. Barclays PLC now owns 40,374 shares of the company’s stock worth $222,000 after acquiring an additional 22,597 shares during the period. Nantahala Capital Management LLC grew its stake in shares of ARS Pharmaceuticals by 45.3% in the fourth quarter. Nantahala Capital Management LLC now owns 1,596,504 shares of the company’s stock worth $8,749,000 after acquiring an additional 497,429 shares during the period. Creative Planning grew its stake in shares of ARS Pharmaceuticals by 11.7% in the fourth quarter. Creative Planning now owns 31,201 shares of the company’s stock worth $171,000 after acquiring an additional 3,270 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $423,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.